NMLSF NOVA MENTIS LIFE SCIENCE CORP
- 0.010900
- -0.000700-6.03%
NOVA MENTIS LIFE SCIENCE CORP News
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ:MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a t
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC:NMLSF) has started recruiting participants for the first-ever clinical trial assessing
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
Wellbeing Digital (OTC:KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a g
Nova Mentis Life Science Appoints Executive Chairman
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
Psychedelics biotechs Nova Mentis Life Science Corp. (OTCQB:NMLSF) and Wellbeing Digital Sciences Inc. (OTC:KONEF)'s subsidiary KGK Sciences Inc. have submitted the first-ever Phase 2a Clinical Trial
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
Psychedelics company Wellbeing Digital Sciences Inc. (OTC:KONEF)'s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science Corp.
Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn
Nova Mentis Life Science Corp. (OTCQB:NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry, manufactur
New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
Canadian-based psychedelics company Nova Mentis Life Science Corp. (OTCQB:NMLSF), or NOVA, is collaborating with the Toronto Institute of Pharmaceutical Technology (TIPT), a Health Canada-licensed GMP
More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
The Canadian biotech company Nova Mentis Life Science Corp. (OTCQB:NMLSF) is filing new provisional patent applications to the U.S. Patent and Trademark Office (USPTO) in order to protect potential co
Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened
Nova Mentis Life Science Corp. (OTCQB:NMLSF), also known as NOVA, a biotech company developing psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, recently rec
Nova Mentis gets required U.S. DEA export approval for its psilocybin drug NM-1001
Nova Mentis Life Science (OTCQB:NMLSF) on Tuesday said it had got a required export approval from the U.S. Drug Enforcement Administration for its psilocybin drug NM-1001. The drug has been exported a
Nova Mentis Is Looking To Treat Autism With Psilocybin
Nova Mentis Life Science Corp. (OTCQB:NMLSF) and the private college Toronto Institute of Pharmaceutical Technology have signed a contract for the production of psilocybin capsules. The company will s
This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism
Nova Mentis Life Science Corp (OTCQB:NMLSF) is a biotechnology company focused on psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. The stock is currently tr
Nova Mentis names new CFO
Biotechnology company, Nova Mentis Life Science (OTCQB:NMLSF) announces appointment of Rebecca Hudson as its CFO, adding corporate finance, accounting and risk management experience to the company's m
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Detroit Decriminalizes Psychedelics Detroit is the latest to join the growing list of U.S. cities that have decriminalized psychedelic substances. The measure under which the Motor City will “decrimin
Magic Mushrooms and Ecstasy: New Treatment For Autism Spectrum Disorders?
Much like cannabis, psychedelics are catching the eye of investors for their potential to break out of their classification of scheduled substances and move closer to becoming valuable tools in the tr
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
The Week In Psychedelics British Prime Minister Boris Johnson To Consider Psilocybin Legalization Nova Mentis and Mycrodose Partner To Research Psilocybin For Autism Fourth Massachusetts City Decrimin
Pre-market: Dow futures rose 0.2%, Disney rose more than 5%
US stock index futures had mixed ups and downs before Friday's session. No important data was released today. Recently, trading volume in the US stock market has been sluggish because many traders and fund managers are on vacation. Among the S&P 500's constituent stocks, 86% of the companies that have submitted financial reports have exceeded analysts' expectations. As of press release, Dow futures rose 0.2%, S&P 500 futures rose 0.02%, and NASDAQ futures fell 0.1%. The UK FTSE 100 index rose 0.4%, the German DAX index rose 0.9%, and the French CAC-40 index rose 0.3%. The dollar continued to consolidate near a four-month high. Spot gold
Analysis
Price Target
No Data
